This feature highlights changes in clinical trial organizations’ personnel.
Sergio Quezada has been appointed to the position of chief scientific officer of Achilles Therapeutics. Quezada will continue to serve as professor of cancer immunology and immunotherapy at the University College London Cancer Institute.
Mihriban Tuna has been named chief scientific officer of UK-based Adaptate Biotherapeutics. Prior to this role, Tuna was senior vice president of drug discovery at F-star. Mark Uden was appointed vice president of pharmaceutical sciences at Adaptate, taking this role after his previous position of vice president of pharmaceutical sciences at GammaDelta Therapeutics. Additionally, Oxana Polyakova was appointed head of discovery at Adaptate. Previously, Polyakova was protein and molecular group lead at GammaDelta Therapeutics.
Affimed has found its new chief scientific officer in Arndt Schottelius, who was most recently executive vice president and head of R&D at Kymab Group.
Tasos Konidaris has been appointed to the role of senior vice president, chief financial officer of Amneal Pharmaceuticals. Most recently, Konidaris was chief financial officer of Alcresta Therapeutics.
Flagship Pioneering has launched Repertoire Immune Medicines, with John Cox taking the helm as the company’s CEO. Cox was most recently CEO of Torque Therapeutics.
Christine Vannais is now chief operating officer of FUJIFILM Diosynth Biotechnologies. Prior to joining FUJIFILM in 2012, Vannais was safety, health and environmental manager at Merck Animal Health.
Thomas Isett has been named CEO of iBio. Previously, Isett was managing director of i.e. Advising, a strategy and consulting company.
Impulse Dynamics has appointed Ishu Rao to the role of medical director. Rao was most previously a self-employed cardiac electrophysiologist.
Douglas Onsi will now serve as president and CEO of Leap, a promotion from his previous chief financial officer position at the company. Leap has also promoted Cynthia Sirard from the role of vice president of clinical R&D to the position of chief medical officer. Also, Leap has promoted Mark O’Mahony to the role of chief manufacturing officer. O’Mahony was most recently Leap’s vice president of manufacturing.
Merz Aesthetics has named Samantha Kerr chief medical officer, tapping her from Allergan, where she served as vice president and global area head of medical aesthetics and devices.
Morphic Therapeutic has announced the hiring of Peter Linde, who will serve as chief medical officer. Prior to this role, Linde served as vice president of medical research at Acceleron Pharma.
Matthew Baker has been named CEO of NeoPhore. Prior, Baker was chief scientific officer of Denceptor Therapeutics.
Santen has promoted chief operating officer Shigeo Taniuchi to the role of CEO. Takahiro Morita, Santen’s head of sales, has also been promoted to the company’s head of marketing. Santen promoted Minori Hara, general manager of global information security and governance group, to the role of chief information officer. Tatsuya Kaihara, Santen’s previous chief strategy officer, has been promoted to head the company’s North America business.
Mark Bridgewater has joined UK-based Vectura as the company’s new chief commercial officer. Bridgewater was most recently vice president of business development and account management for Europe and Asia at Flex Health Solutions.